Theorem Clinical Research

R&D Trends

BioMotiv, Takeda partner for medical innovation

Monday, September 29, 2014 01:06 PM

Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has invested in BioMotiv, a therapeutic accelerator company associated with the Ohio-based Harrington Project for Discovery & Development, and they have partnered to identify and develop pioneering medical innovations.

More... »


Medimmune, Cancer Research U.K. establish laboratory for biologic cancer medicines

Friday, September 26, 2014 03:24 PM

MedImmune, AstraZeneca’s global biologics R&D arm, and Cancer Research U.K., with its commercial arm Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, U.K. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period.

More... »


Soligenix awarded $24.7M NIAID contract for heat stable RiVax vaccine

Friday, September 26, 2014 03:05 PM

Soligenix, a Princeton, N.J.-based late-stage biopharmaceutical company developing products that address unmet medical needs in inflammation, oncology and biodefense, has been awarded a contract valued at up to $24.7 million inclusive of options by the U.S. Department of Health and Human Service's NIH, specifically funded by the National Institute of Allergy and Infectious Diseases (NIAID). The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

More... »

Thermo Fisher Scientific inks agreement with GlaxoSmithKline, Pfizer

Friday, September 26, 2014 03:01 PM

Thermo Fisher Scientific, a Waltham, Mass.-based healthcare equipment company, has inked an agreement with GlaxoSmithKline and Pfizer to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs.

More... »

Aethlon Medical, Exosome Sciences to collaborate with BU CTE Center

Friday, September 26, 2014 03:00 PM

Aethlon Medical and its New Jersey-based diagnostic subsidiary Exosome Sciences (ESI) have established a clinical collaboration with the Boston University (BU) CTE Center to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.

More... »

Baxter, Merrimack Pharmaceuticals ink agreement for MM-398

Thursday, September 25, 2014 12:50 PM

Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as nal-IRI. Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the U.S. and Taiwan, and Merrimack retains commercialization rights in the U.S.; the rights in Taiwan are held separate/news-online/company/EMAly.

More... »

Atara Biotherapeutics, Memorial Sloan-Kettering Cancer Center ink agreement

Wednesday, September 24, 2014 01:25 PM

Atara Biotherapeutics, a California-based, privately held drug development company, has entered into an exclusive option agreement with New York’s Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies, consisting of:

More... »

Tekmira joins consortium conducting Ebola virus trials in West Africa

Wednesday, September 24, 2014 01:22 PM

Tekmira Pharmaceuticals, a British Columbia-based developer of RNA interference (RNAi) therapeutics, is collaborating with an international consortium to provide an RNAi-based investigational therapeutic for expedited clinical studies in West Africa.

More... »

Navidea awarded $1.67M to evaluate Lymphoseek for cervical cancer

Wednesday, September 24, 2014 01:20 PM

Navidea Biopharmaceuticals, a Dublin, Ohio developer of precision diagnostics and radiopharmaceutical agents, has received an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.67 million from the National Cancer Institute (NCI), a part of the NIH, to fund evaluation of Lymphoseek (technetium Tc 99m tilmanocept) Injection in women with cervical cancer.

More... »

Study: Finding contributions and needs of life sciences industry in New Jersey

Monday, September 22, 2014 02:32 PM

Recognizing the continuing evolution of New Jersey’s life sciences industry, BioNJ has released a comprehensive report that documents the ongoing growth of the biotechnology sector in the state and combines and assesses the contributions of the entirety of the life sciences sector to New Jersey’s economy, including employment and economic impact.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs